GlobalData analysed all terminated trials within the Clinical Trials Database and found the top five therapy areas by trial count to be Oncology, Central Nervous System, Cardiovascular, Infectious Disease, and Metabolic Disorders, in descending order.

The largest phase of termination occurred in Phase II in all therapeutic areas (Figure 1), as well as across all terminated trials. Overall, Phase II accounted for 50% of all terminated trials and Oncology was the only therapy area that exceeded this, where 65% of all Phase II trials were terminated.

The biggest reason for trial discontinuation in Oncology was “low accrual rate,” at 35% of all terminated trials with reasons given. This was followed by “unspecified” at 25%, “other” at 16%, “lack of efficacy” at 10%, and “adverse events” at 6% rounding out the top five reasons.

Image: Top five therapy areas in terminated trials. Credit: GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.